FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892300305> ?p ?o ?g. }

• W2892300305 abstract "Cancer cell metabolism requires sustained pools of intracellular nicotinamide adenine dinucleotide (NAD+) which is maintained by a balance of NAD+ hydrolase activity and NAD+ salvage activity. We recently reported that human prostate cancer can be initiated following oncogene expression in progenitor-like luminal cells marked by low expression of the NAD+-consuming enzyme CD38. CD38 expression is reduced in prostate cancer compared to benign prostate, suggesting that tumor cells may reduce CD38 expression in order to enhance pools of NAD+. However, little is known about how CD38 expression is repressed in advanced prostate cancer and whether CD38 plays a role in regulating NAD+ levels in prostate epithelial cells.CD38 expression, its association with recurrence after prostatectomy for clinically localized prostate cancer, and DNA methylation of the CD38 promoter were evaluated in human prostate tissues representing various stages of disease progression. CD38 was inducibly over-expressed in benign and malignant human prostate cell lines in order to determine the effects on cell proliferation and levels of NAD+ and NADH. NAD+ and NADH were also measured in urogenital tissues from wild-type and CD38 knockout mice.CD38 mRNA expression was reduced in metastatic castration-resistant prostate cancer compared to localized prostate cancer. In a large cohort of men undergoing radical prostatectomy, CD38 protein expression was inversely correlated with recurrence. We identified methylation of the CD38 promoter in primary and metastatic prostate cancer. Over-expression of wild-type CD38, but not an NAD+ hydrolase-deficient mutant, depleted extracellular NAD+ levels in benign and malignant prostate cell lines. However, expression of CD38 did not significantly alter intracellular NAD+ levels in human prostate cell lines grown in vitro and in urogenital tissues isolated from wild-type and CD38 knockout mice.CD38 protein expression in prostate cancer is associated with risk of recurrence. Methylation results suggest that CD38 is epigenetically regulated in localized and metastatic prostate cancer tissues. Our study provides support for CD38 as a regulator of extracellular, but not intracellular, NAD+ in epithelial cells. These findings suggest that repression of CD38 by methylation may serve to increase the availability of extracellular NAD+ in prostate cancer tissues." @default.
• W2892300305 created "2018-09-27" @default.
• W2892300305 creator A5022256674 @default.
• W2892300305 creator A5024041740 @default.
• W2892300305 creator A5028420362 @default.
• W2892300305 creator A5037036753 @default.
• W2892300305 creator A5045356809 @default.
• W2892300305 creator A5046387277 @default.
• W2892300305 creator A5047395289 @default.
• W2892300305 creator A5047882814 @default.
• W2892300305 creator A5061239169 @default.
• W2892300305 creator A5063643925 @default.
• W2892300305 creator A5068348417 @default.
• W2892300305 creator A5068903724 @default.
• W2892300305 creator A5070990818 @default.
• W2892300305 creator A5083311052 @default.
• W2892300305 creator A5083333223 @default.
• W2892300305 creator A5086896931 @default.
• W2892300305 creator A5091314004 @default.
• W2892300305 date "2018-09-21" @default.
• W2892300305 modified "2023-10-14" @default.
• W2892300305 title "CD38 is methylated in prostate cancer and regulates extracellular NAD+" @default.
• W2892300305 cites W1246965181 @default.
• W2892300305 cites W131012821 @default.
• W2892300305 cites W144938133 @default.
• W2892300305 cites W1483624903 @default.
• W2892300305 cites W1563310200 @default.
• W2892300305 cites W1902692042 @default.
• W2892300305 cites W1908827878 @default.
• W2892300305 cites W1929811497 @default.
• W2892300305 cites W1959721425 @default.
• W2892300305 cites W1968271489 @default.
• W2892300305 cites W1969545527 @default.
• W2892300305 cites W1971693621 @default.
• W2892300305 cites W1996386813 @default.
• W2892300305 cites W1997308033 @default.
• W2892300305 cites W2005274657 @default.
• W2892300305 cites W2009071437 @default.
• W2892300305 cites W2019164724 @default.
• W2892300305 cites W2020579083 @default.
• W2892300305 cites W2032970890 @default.
• W2892300305 cites W2033230341 @default.
• W2892300305 cites W2034879676 @default.
• W2892300305 cites W2038011036 @default.
• W2892300305 cites W2042081254 @default.
• W2892300305 cites W2043486701 @default.
• W2892300305 cites W2049700579 @default.
• W2892300305 cites W2052639550 @default.
• W2892300305 cites W2066235353 @default.
• W2892300305 cites W2070924431 @default.
• W2892300305 cites W2071425861 @default.
• W2892300305 cites W2071555363 @default.
• W2892300305 cites W2072259475 @default.
• W2892300305 cites W2072356438 @default.
• W2892300305 cites W2075085753 @default.
• W2892300305 cites W2075124455 @default.
• W2892300305 cites W2081365151 @default.
• W2892300305 cites W2082340361 @default.
• W2892300305 cites W2092308569 @default.
• W2892300305 cites W2097361448 @default.
• W2892300305 cites W2100305481 @default.
• W2892300305 cites W2105504226 @default.
• W2892300305 cites W2108234281 @default.
• W2892300305 cites W2112866277 @default.
• W2892300305 cites W2114843025 @default.
• W2892300305 cites W2115314035 @default.
• W2892300305 cites W2118982164 @default.
• W2892300305 cites W2119228184 @default.
• W2892300305 cites W2119798638 @default.
• W2892300305 cites W2124826140 @default.
• W2892300305 cites W2130955565 @default.
• W2892300305 cites W2137547257 @default.
• W2892300305 cites W2141091746 @default.
• W2892300305 cites W2141831115 @default.
• W2892300305 cites W2156558356 @default.
• W2892300305 cites W2161112598 @default.
• W2892300305 cites W2161224111 @default.
• W2892300305 cites W2162250780 @default.
• W2892300305 cites W2169353806 @default.
• W2892300305 cites W2169456326 @default.
• W2892300305 cites W2262087934 @default.
• W2892300305 cites W2322945529 @default.
• W2892300305 cites W2343193821 @default.
• W2892300305 cites W2427895239 @default.
• W2892300305 cites W2473747534 @default.
• W2892300305 cites W2517346518 @default.
• W2892300305 cites W2553118400 @default.
• W2892300305 cites W2560367415 @default.
• W2892300305 cites W2560495570 @default.
• W2892300305 cites W2597130646 @default.
• W2892300305 cites W2775008495 @default.
• W2892300305 cites W2776792976 @default.
• W2892300305 cites W2781525129 @default.
• W2892300305 cites W2782262358 @default.
• W2892300305 cites W2791758888 @default.
• W2892300305 cites W4251284458 @default.
• W2892300305 doi "https://doi.org/10.1186/s40170-018-0186-3" @default.
• W2892300305 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6150989" @default.
• W2892300305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30258629" @default.
• W2892300305 hasPublicationYear "2018" @default.

• next